Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Metastatic Tumors
Interventions
RADIATION

Stereotactic ablative radiotherapy

Total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks.

RADIATION

palliative radiotherapy

"Investigators should follow the principles of palliative radiotherapy as per the individual institution. Treatment recommendations are as follows:~Brain: Whole brain radiotherapy i.e. 20 Gy in 5 fractions, 30 Gy in 10 fractions~Lung: Palliative radiotherapy as per 2011 consensus guidelines.15 i.e. 8 Gy in 1 fraction, 20 Gy in 5 fractions, 30 Gy in 10 fractions~Bone: Palliative radiotherapy as per 2011 consensus guidelines.16 i.e. 8 Gy in 1 fraction (most common), 20 Gy in 5 fractions, 30 Gy in 10 fractions~Liver: 20 Gy in 5 fractions if standard institutional practice"

Trial Locations (10)

3004

Alfred Health, William Burkland Radiotherapy Centre, Melbourne

V5Z4E6

BC Cancer Agency, Vancouver

B3H 1V7

Atlantic Clinical Cancer Research , QEII Health Sciences Centre, Halifax

L8V 5C2

Juravinski Cancer Centre, Hamilton Health Sciences, Hamilton

N6A 4L6

London Regional Cancer Program of the Lawson Health Research Institute, London

Unknown

Ottawa Cancer Centre, Ottawa

VU University Amsterdam (VUmc), Amsterdam

The Beatson West of Scotland Cancer Centre, Glasgow

C1A 8T5

PEI Cancer Treatment Center, Charlottetown

H3H 1A4

McGill University Health Centre Research Institute, Montreal

All Listed Sponsors
collaborator

London Regional Cancer Program, Canada

OTHER

collaborator

VU University of Amsterdam

OTHER

lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER